PUBLISHER: The Business Research Company | PRODUCT CODE: 1951738
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951738
Drugs for immunotherapy are medications designed to either stimulate or suppress the immune system to help the body defend itself against cancer, infections, and other diseases. Immunotherapy is a form of treatment that assists the immune system in recognizing and combating cancer, while also supporting the body's natural ability to fight infections and various disorders.
The primary types of drugs used in immunotherapy include monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are produced by cloning a single white blood cell, with all resulting antibodies originating from one parent cell. These therapies are applied across areas such as cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and are utilized in sectors including hospitals and clinics, ambulatory surgical centers, and others.
Tariffs have impacted the drugs for immunotherapy market by increasing costs for imported biologics, monoclonal antibodies, vaccines, and related reagents. Segments like monoclonal antibodies, checkpoint inhibitors, and therapeutic vaccines are most affected, with North America, Europe, and Asia-Pacific regions reliant on imports facing higher expenses and supply delays. However, tariffs have also encouraged domestic production, investment in local R&D, and development of cost-optimized immunotherapy solutions.
The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with a drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drugs for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $310.48 billion in 2025 to $349.53 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited immunotherapy options, reliance on conventional cancer treatments, growing incidence of cancer and autoimmune diseases, increasing clinical trials for monoclonal antibodies, rising healthcare infrastructure.
The drugs for immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $570 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to development of bispecific and conjugated antibodies, expansion of personalized immunotherapy, increasing adoption of checkpoint inhibitors, rising investments in therapeutic vaccine research, integration of digital patient monitoring and AI-guided immunotherapy. Major trends in the forecast period include rising adoption of monoclonal antibodies and checkpoint inhibitors, growth in cancer immunotherapy and autoimmune disease treatments, increasing development of therapeutic and preventive vaccines, expansion of t-cell receptor and cytokine-based therapies, integration of immunotherapy in ambulatory and hospital-based care.
The rising level of healthcare expenditure is expected to drive the growth of the drugs for immunotherapy market in the coming years. Healthcare expenditure represents the total spending on healthcare products and services within a specific region or country over a given period, including costs related to physician consultations, hospitalizations, surgical procedures, diagnostic services, and medical treatments. Financial resources for healthcare are provided by individuals, healthcare providers, insurance organizations, and government bodies to support the cost of immunotherapy drugs and related treatments. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering Medicare and Medicaid, healthcare spending in the United States increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. As a result, increasing healthcare expenditure is contributing to the expansion of the drugs for immunotherapy market.
Major companies operating in the drugs for immunotherapy market are concentrating on the development of innovative products, such as Keytruda (pembrolizumab), to deliver effective and reliable treatment options. Keytruda is an immunotherapy drug classified as an immune checkpoint inhibitor and is used as a targeted therapy for adult patients. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched Keytruda (pembrolizumab) following approval from the Food and Drug Administration. Keytruda is used to treat multiple types of cancer by activating the immune system to recognize and attack cancer cells and is approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This approval represents an important advancement in cancer therapy and is expected to positively influence the healthcare sector.
In December 2024, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by expanding into advanced immunotherapy approaches, particularly through Seagen's antibody-drug conjugate technologies for targeted cancer treatment. Seagen Inc. is a US-based biotechnology company specializing in the development and manufacturing of antibody-drug conjugates.
Major companies operating in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., UbiVac, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.
North America was the largest region in the immunotherapy market in 2025. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drugs for Immunotherapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drugs for immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drugs for immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drugs for immunotherapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.